To unlock this feature and to subscribe to our weekly evidence emails, please create a FREE orthoEvidence account.

SIGNUP

Already Have an Account?

Loading...
Visit our Evidence-Based Covid-19 Website and Stay Up to Date with the latest Research.
Ace Report Cover

TNF antagonist better in treatment of early rheumatoid arthritis

Download
Share
Reprints
Cite This
About
+ Favorites
Share
Reprints
Cite This
About
+ Favorites
Author Verified
Ace Report Cover
May 2013

TNF antagonist better in treatment of early rheumatoid arthritis

Vol: 2| Issue: 4| Number:126| ISSN#: 2564-2537
Study Type:Therapy
OE Level Evidence:2
Journal Level of Evidence:N/A

Addition of infliximab compared with addition of sulfasalazine and hydroxychloroquine to methotrexate in patients with early rheumatoid arthritis (Swefot trial): 1-year results of a randomised trial

Lancet. 2009 Aug 8;374(9688):459-66.

Contributing Authors:
RF van Vollenhoven S Ernestam P Geborek IF Petersson L Cöster E Waltbrand A Zickert J Theander A Thörner H Hellström A Teleman C Dackhammar F Akre K Forslind L Ljung R Oding A Chatzidionysiou M Wörnert J Bratt

Did you know you're eligible to earn 0.5 CME credits for reading this report? Click Here

Synopsis

258 patients with early stage rheumatoid arthritis, who were unresponsive to 4 months treatment with methotrexate, were randomized to receive additional treatment with Infliximab (tumor necrosis factor antagonist) or sulfasalazine and hydroxychloroquine. This trial assessed the efficacy of the use of tumor necrosis factor antagonists in treatment of rheumatoid arthritis, while comparing this treat...

CME Image

Did you know that you’re eligible to earn 0.5 CME credits for reading this report!

LEARN MORE

Join the Conversation

Please Login or Join to leave comments.

Learn about our AI Driven
High Impact Search Feature

High Impact Icon

Our AI driven High Impact metric calculates the impact an article will have by considering both the publishing journal and the content of the article itself. Built using the latest advances in natural language processing, OE High Impact predicts an article’s future number of citations better than impact factor alone.

Continue